Digital Biomarkers (May 2023)
Reverse Engineering of Digital Measures: Inviting Patients to the Conversation
- Ieuan Clay,
- Nele Peerenboom,
- Dana E Connors,
- Steven Bourke,
- Alison Keogh,
- Katarzyna Wac,
- Tova Gur-Arie,
- Justin Baker,
- Christopher Bull,
- Andrea Cereatti,
- Francesca Cormack,
- Damien Eggenspieler,
- Luca Foschini,
- Raluca Ganea,
- Peter MA Groenen,
- Nicole Gusset,
- Elena Izmailova,
- Christoph M Kanzler,
- Lada Leyens,
- Kate Lyden,
- Arne Mueller,
- Julian Nam,
- Wan-Fai Ng,
- David Nobbs,
- Foteini Orfaniotou,
- Thanneer Malai Perumal,
- Wojciech Piwko,
- Anja Ries,
- Alf Scotland,
- Nick Taptiklis,
- John Torous,
- Beatrix Vereijken,
- Shuai Xu,
- Laurenz Baltzer,
- Thorsten Vetter,
- Jörg Goldhahn,
- Steven C Hoffmann
Affiliations
- Ieuan Clay
- ORCiD
- VivoSense Inc., Newport Beach, CA, USA
- Nele Peerenboom
- ORCiD
- VivoSense Inc., Newport Beach, CA, USA
- Dana E Connors
- ORCiD
- The Foundation for the NIH, North Bethesda, MD, USA
- Steven Bourke
- ORCiD
- PersonalPulse GmbH, Basel, Switzerland
- Alison Keogh
- ORCiD
- Insight Centre for Data Analytics, UC Dublin, Dublin, Ireland
- Katarzyna Wac
- ORCiD
- Quality of Life Lab, University of Geneva, Geneva, Switzerland
- Tova Gur-Arie
- Mobilise-D, Newcastle University, Newcastle upon Tyne, UK
- Justin Baker
- ORCiD
- Harvard Medical School, Cambridge, MA, USA
- Christopher Bull
- ORCiD
- Newcastle University, Newcastle, UK
- Andrea Cereatti
- Mobilise-D, Newcastle University, Newcastle upon Tyne, UK
- Francesca Cormack
- ORCiD
- IDEA-FAST, Newcastle University, Newcastle upon Tyne, UK
- Damien Eggenspieler
- Sysnav Healthcare, Vernon, France
- Luca Foschini
- Sage Bionetworks, Seattle, WA, USA
- Raluca Ganea
- ORCiD
- SHL Medical, Zug, Switzerland
- Peter MA Groenen
- ORCiD
- Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland
- Nicole Gusset
- SMA Schweiz, Heimberg, Switzerland
- Elena Izmailova
- ORCiD
- Koneksa Health, New York, NY, USA
- Christoph M Kanzler
- Biogen Digital Health International GmbH, Baar, Switzerland
- Lada Leyens
- F. Hoffmann-La Roche, Basel, Switzerland
- Kate Lyden
- VivoSense Inc., Newport Beach, CA, USA
- Arne Mueller
- ORCiD
- Mobilise-D, Newcastle University, Newcastle upon Tyne, UK
- Julian Nam
- ORCiD
- F. Hoffmann-La Roche, Basel, Switzerland
- Wan-Fai Ng
- Newcastle University, Newcastle, UK
- David Nobbs
- ORCiD
- IDEA-FAST, Newcastle University, Newcastle upon Tyne, UK
- Foteini Orfaniotou
- ORCiD
- F. Hoffmann-La Roche, Basel, Switzerland
- Thanneer Malai Perumal
- ORCiD
- F. Hoffmann-La Roche, Basel, Switzerland
- Wojciech Piwko
- Takeda Pharmaceuticals International, Zurich, Switzerland
- Anja Ries
- ORCiD
- F. Hoffmann-La Roche, Basel, Switzerland
- Alf Scotland
- Biogen Digital Health International GmbH, Baar, Switzerland
- Nick Taptiklis
- IDEA-FAST, Newcastle University, Newcastle upon Tyne, UK
- John Torous
- ORCiD
- Harvard Medical School, Cambridge, MA, USA
- Beatrix Vereijken
- ORCiD
- Mobilise-D, Newcastle University, Newcastle upon Tyne, UK
- Shuai Xu
- Sibel Health, Niles, IL, USA
- Laurenz Baltzer
- ORCiD
- Swiss Federal Institute of Technology, Zurich, Switzerland
- Thorsten Vetter
- European Medicines Agency, Amsterdam, The Netherlands
- Jörg Goldhahn
- ORCiD
- Swiss Federal Institute of Technology, Zurich, Switzerland
- Steven C Hoffmann
- ORCiD
- The Foundation for the NIH, North Bethesda, MD, USA
- DOI
- https://doi.org/10.1159/000530413
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 28 – 44
Abstract
Background: Digital measures offer an unparalleled opportunity to create a more holistic picture of how people who are patients behave in their real-world environments, thereby establishing a better connection between patients, caregivers, and the clinical evidence used to drive drug development and disease management. Reaching this vision will require achieving a new level of co-creation between the stakeholders who design, develop, use, and make decisions using evidence from digital measures. Summary: In September 2022, the second in a series of meetings hosted by the Swiss Federal Institute of Technology in Zürich, the Foundation for the National Institutes of Health Biomarkers Consortium, and sponsored by Wellcome Trust, entitled “Reverse Engineering of Digital Measures,” was held in Zurich, Switzerland, with a broad range of stakeholders sharing their experience across four case studies to examine how patient centricity is essential in shaping development and validation of digital evidence generation tools. Key Messages: In this paper, we discuss progress and the remaining barriers to widespread use of digital measures for evidence generation in clinical development and care delivery. We also present key discussion points and takeaways in order to continue discourse and provide a basis for dissemination and outreach to the wider community and other stakeholders. The work presented here shows us a blueprint for how and why the patient voice can be thoughtfully integrated into digital measure development and that continued multistakeholder engagement is critical for further progress.
Keywords